PHYOXTM Clinical Trial Program
The Company’s lead GalXCTM product candidate, DCR-PHXC, now referred to as nedosiran, is in clinical development for the treatment of Primary Hyperoxaluria (PH). The PHYOX2 clinical trial is enrolling patients with PH type 1 (PH1) and PH type 2 (PH2). For more information about the PHYOXTM clinical trial program or to find the clinical trial sites, please contact Dicerna at email@example.com or go to https://www.clinicaltrials.gov/ct2/show/NCT03847909.
Please note, depending on a person’s eligibility to participate in the clinical trial, expenses to travel to a clinical trial site will be covered by Dicerna.
Participating in a Trial
Physicians at leading research institutions who specialize in the treatment of PH are conducting the PHYOXTM clinical trials. If you or a loved one has been diagnosed with PH and would like to participate in a clinical trial, please submit your information through the form below:
Eligibility Form Coming Soon – Please Check Back Soon
For more information on the trial, please view the Frequently Asked Questions page, visit clinicaltrials.gov and enter the identifier number NCT03847909 or click on the following link: https://www.clinicaltrials.gov/ct2/show/NCT03847909.